CFO Nathan Hardy resigns effective October 4, 2024

Sana Biotechnology, Inc.

Nathan Hardy notified resignation as EVP and CFO on September 6, 2024, effective October 4, 2024.
Resignation is voluntary for personal reasons; no disagreement with company operations or policies.
No successor has been announced; CFO duties will be assumed by interim arrangement or search process.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nathan Hardy

Executive Vice President and Chief Financial Officer

SANA · Sana Biotechnology, Inc.

Effective: 2024-10-04
Filed: September 12, 2024, 7:59 PM ET

On September 6, 2024, Nathan Hardy notified Sana Biotechnology, Inc. (the “Company”) that he intends to resign from his position as Executive Vice President and Chief Financial Officer of the Company effective October 4, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nathan Hardy resigned as Executive Vice President and Chief Financial Officer at Sana Biotechnology, Inc..

Action: resigned
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

On September 6, 2024, Nathan Hardy notified Sana Biotechnology, Inc. (the “Company”) that he intends to resign from his position as Executive Vice President and Chief Financial Officer of the Company effective October 4, 2024.

View on SEC.gov

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-218049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.